F
Fred S. Gorelick
Researcher at Yale University
Publications - 182
Citations - 9124
Fred S. Gorelick is an academic researcher from Yale University. The author has contributed to research in topics: Acinar cell & Pancreatitis. The author has an hindex of 53, co-authored 175 publications receiving 8329 citations. Previous affiliations of Fred S. Gorelick include Rockefeller University & Veterans Health Administration.
Papers
More filters
Journal ArticleDOI
Models of Acute and Chronic Pancreatitis
Markus M. Lerch,Fred S. Gorelick +1 more
TL;DR: Animal models of acute and chronic pancreatitis have been created to examine mechanisms of pathogenesis, test therapeutic interventions, and study the influence of inflammation on the development of pancreatic cancer.
Journal ArticleDOI
Gamma-secretase activating protein is a therapeutic target for Alzheimer’s disease
Gen-Lin He,Wenjie Luo,Peng Li,Christine L. Remmers,William J. Netzer,Joseph P. Hendrick,Karima Bettayeb,Marc Flajolet,Fred S. Gorelick,Lawrence P. Wennogle,Paul Greengard +10 more
TL;DR: It is demonstrated that imatinib, an anticancer drug previously found to inhibit amyloid-β formation without affecting Notch cleavage, achieves its amyloids-β-lowering effect by preventing GSAP interaction with the γ-secretase substrate, APP-CTF.
Journal ArticleDOI
Localization of the cystic fibrosis transmembrane conductance regulator in pancreas.
TL;DR: The findings suggest that proximal duct epithelial cells play a key role in the early events leading to pancreatic insufficiency in CF, and imply that apical chloride transport by these cells is essential for normal pancreatic secretory function.
Journal ArticleDOI
Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits
Daniel J. Drucker,Steven I. Sherman,Fred S. Gorelick,Richard M. Bergenstal,Robert S. Sherwin,John B. Buse +5 more
TL;DR: No currently available agents exhibit the ideal profile of exceptional glucose-lowering efficacy to safely achieve target levels of glycemia in a broad range of patients, so highly efficacious agents that exhibit unimpeachable safety, excellent tolerability, and ease of administration are needed.
Journal ArticleDOI
Lactate reduces liver and pancreatic injury in Toll-like receptor- and inflammasome-mediated inflammation via GPR81-mediated suppression of innate immunity.
Rafaz Hoque,Ahmad Farooq,Ayaz Ghani,Fred S. Gorelick,Fred S. Gorelick,Wajahat Z. Mehal,Wajahat Z. Mehal +6 more
TL;DR: In this paper, the authors examined whether lactate and the lactate receptor, G i -protein-coupled receptor 81 (GPR81), regulate TLR induction of signal 1 and limit inflammasome activation and organ injury.